{"id":"sr-fampridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Seizures"},{"rate":null,"effect":"Urinary tract infection"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4591082","moleculeType":"Unknown","molecularWeight":"622.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fampridine is a broad-spectrum potassium channel blocker that increases the duration of the action potential in demyelinated nerve fibers, thereby improving conduction across damaged segments. The sustained-release formulation allows for twice-daily dosing with improved tolerability compared to immediate-release formulations. This mechanism is particularly beneficial in demyelinating diseases where nerve conduction is impaired.","oneSentence":"SR-fampridine is a sustained-release formulation of fampridine that blocks potassium channels in nerve fibers, prolonging action potentials and enhancing nerve conduction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:59.297Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (to improve walking ability)"},{"name":"Spinal cord injury"}]},"trialDetails":[{"nctId":"NCT06751784","phase":"PHASE2","title":"Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression","status":"RECRUITING","sponsor":"University of Basel","startDate":"2025-05-22","conditions":"Working Memory, Mild to Moderate Depression","enrollment":38},{"nctId":"NCT04516603","phase":"PHASE2","title":"Influence of Fampridine on Working Memory in Healthy Subjects","status":"WITHDRAWN","sponsor":"Prof. Dominique de Quervain, MD","startDate":"2040-01-01","conditions":"Working Memory","enrollment":""},{"nctId":"NCT05274477","phase":"NA","title":"Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment","status":"TERMINATED","sponsor":"Prof. Dominique de Quervain, MD","startDate":"2022-06-28","conditions":"Working Memory, Post-covid-19","enrollment":8},{"nctId":"NCT04652557","phase":"PHASE2","title":"Influence of Fampridine on Working Memory in Healthy Young Subjects","status":"COMPLETED","sponsor":"Prof. Dominique de Quervain, MD","startDate":"2021-11-01","conditions":"Working Memory","enrollment":44},{"nctId":"NCT04148781","phase":"EARLY_PHASE1","title":"Fampridine-SR and Optic Neuritis Recovery","status":"UNKNOWN","sponsor":"Courtney Casserly","startDate":"2022-03-22","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT00041717","phase":"PHASE3","title":"Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2002-07","conditions":"Spinal Cord Injury, Muscle Spasticity","enrollment":213},{"nctId":"NCT00127530","phase":"PHASE3","title":"Study of Oral Fampridine-SR in Multiple Sclerosis","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2005-05","conditions":"Multiple Sclerosis","enrollment":300},{"nctId":"NCT01656148","phase":"PHASE4","title":"FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2012-06","conditions":"Multiple Sclerosis","enrollment":108},{"nctId":"NCT02143167","phase":"PHASE4","title":"Resistance Training and Amino Pyridine in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2014-05","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT01621113","phase":"PHASE2","title":"Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury","status":"COMPLETED","sponsor":"Kessler Foundation","startDate":"2012-06","conditions":"Spinal Cord Injury","enrollment":27},{"nctId":"NCT01683838","phase":"PHASE3","title":"Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2002-06","conditions":"Spinal Cord Injury, Muscle Spasticity","enrollment":204},{"nctId":"NCT00483652","phase":"PHASE3","title":"Study of Fampridine-SR Tablets in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT01667497","phase":"PHASE2, PHASE3","title":"Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?","status":"COMPLETED","sponsor":"London Health Sciences Centre","startDate":"2012-09","conditions":"Cognitive Fatigue","enrollment":60},{"nctId":"NCT01235221","phase":"PHASE3","title":"Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-12","conditions":"Multiple Sclerosis","enrollment":38},{"nctId":"NCT00654927","phase":"PHASE3","title":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2003-11","conditions":"Multiple Sclerosis","enrollment":177},{"nctId":"NCT00649792","phase":"PHASE3","title":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2007-08","conditions":"Multiple Sclerosis","enrollment":214},{"nctId":"NCT00648908","phase":"PHASE3","title":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2006-06","conditions":"Multiple Sclerosis","enrollment":269},{"nctId":"NCT00053417","phase":"PHASE2","title":"Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2003-02","conditions":"Multiple Sclerosis","enrollment":206}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"FALL"},{"count":4,"reaction":"ANAEMIA"},{"count":3,"reaction":"CONDITION AGGRAVATED"},{"count":2,"reaction":"ANGINA UNSTABLE"},{"count":2,"reaction":"CONSTIPATION"},{"count":2,"reaction":"DRUG DOSE OMISSION"},{"count":2,"reaction":"LOSS OF CONSCIOUSNESS"},{"count":2,"reaction":"MALAISE"},{"count":2,"reaction":"MULTIPLE SCLEROSIS"},{"count":2,"reaction":"MUSCLE SPASTICITY"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fampyra"],"phase":"marketed","status":"active","brandName":"SR-fampridine","genericName":"SR-fampridine","companyName":"University of Southern Denmark","companyId":"university-of-southern-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SR-fampridine is a medication used to treat conditions such as Multiple Sclerosis and Working Memory, as indicated by studies on ClinicalTrials.gov. The exact mechanism of SR-fampridine is unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}